SSCI, Inc. Announces Purchase Of Symyx Technologies Discovery Tools

West Lafayette, Indiana - SSCI, Inc., a world leader in solid-state research and contract drug improvement announced today that they have purchased a Symyx Discovery Tools® Core(X)™ module for the purpose of augmenting experimental throughput and data management in polymorph, salt and cocrystal screening and excipient compatibility studies. SSCI has also licensed Symyx's Renaissance® software on an annual right to use basis for use with the Core (X) module.

"We believe the benefits of the Symyx system complement our approach to high-throughput, solid-state screening by offering significant time savings in liquid handling, design of experiments, and data management. We seek to marry the Symyx systems and technologies with methods and techniques developed at SSCI like capillary screening, wellplate-based transmission PXRD, and other proprietary experimental systems. It is clear from the data collected on hundreds of projects that this broad experimental approach will provide our clients with the highest probability of finding the most relevant forms for drug development." said Dr. Pat Stahly, SSCI's Chief Scientific Officer.

Paul Nowak, Symyx's executive vice president and chief operating officer, commented, "Symyx is pleased to be working with SSCI, with the first implementation of our technologies by an organization fully dedicated to pharmaceutical solid-state research and contract drug improvement. This application is a strong complement to our ongoing business with pharmaceutical customers, and demonstrates the flexibility of our Discovery Tools and software to fit the needs of a growing base of customers."

SOURCE: SSCI, Inc.